Current Cancer Therapy Reviews

Kurt S. Zaenker
Institute of Immunology and Experimental Oncology University Witten/Herdecke
Stockumerstraße 10, 58448 Witten


Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Author(s): Eyal C. Attar, Karen K. Ballen.


Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.

Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2006
Page: [199 - 209]
Pages: 11
DOI: 10.2174/157339406777934708
Price: $58